• BTC $8,054.30 (3.76%)
  • ETH $253.57 (4.25%)
  • MARKET CAP $251B
  • ICOs 4,219

Luven Diagnostic

ENDED 271 views
5.2
Total Rate

The LUVEN screening test method created by scientist of our company detects cancer at its early stages with the accuracy of up to 96% only comparable to biopsy. None of the existing diagnostic techniques has such a high diagnostic accuracy. The LUVEN technology allows diagnosing the disease at its early stages , thus, giving a chance to thousands of people to prevent its further development.
General
Website: Visit
White paper: Read
Pre-sale Time: 8 Dec, 2017 - 29 Dec, 2017
ICO Time: 15 Jan, 2018 - 28 Feb, 2018
Country: Ukraine
Token Info
Ticker: LVN
Platform: Ethereum
Token type: ERC20
Available for sale: 30,000,000 LVN
Financial
ICO Price: 290 LVN = 1 ETH
Accepting: ETH, BTC
Social Media
  • 1

    1983

    Development ofthe cancer diagnostic method started, based on the study of buccal cells (cells from the inside ofthe cheek)

  • 2

    2004

    A cytomorphobiologial diagnostic method appeared which formed the basis ofthe diagnostic complex

  • 3

    2010

    Team expansion. A commercial enterprise promoting the LUVEN trademark was established. The software automating a part ofthe diagnostic procedure was created.

  • 4

    2014

    The diagnostic method was patented, completion of the clinicaltrials, creation ofthe software diagnostic complex presented at two international medical exhibitions “The 5th International Medical Forum” and “Health Care 2014”. Opening first franchise outlets.

  • 5

    2015

    In five months after launching a franchise, the contracts were signed with more than twenty outlets, half of which have already run tests on more than two thousand patients. Suspension of activities for a time allowing technology enhancement.

  • 6

    2016 - 2017

    Software enhancement, additional clinicaltrials. Optimizing a big number ofthe system algorithms

  • 7

    September - October 2017

    Preparing and starting a preICO aimed at fundraising for the software enhancement, legal costs and operational expenses ofthe project

  • 8

    January 2018

    Starting an ICO

  • 9

    2018

    Further software enhancement, signing contracts with clinics worldwide for conducting clinicaltrials, opening a research center in Austria. Initiating certification ofthe method in the European Union and Eurasian Union

  • 10

    2019

    Opening 20 new labs in the European Union and Eurasian Union, incorporating a blockchain and developing a domestic exchange for token sale, working on the optical recognition of incoming images ofthe cell, creating a database of patients and their test results for monitoring tendencies and informing patients on the necessity of being diagnosed

  • 11

    2020

    Starting clinicaltrials and certification in the USA and Asia

  • 12

    2021

    Developing home gadgets (a home lab) for running tests on the entire family at any time, launching the product.

Galina Shchukina

Geneticist & Cytologist

Grigory Evglevskiy

CTO

Aleksander Shchukin

Nuclear Physician

Nikolay Shchukin

Postgraduate Student of Chair for Biomedical Engineering

Alexander Kamensky

Principal Software Engineer

Alexander Danilchenko

CEO

Yana Ivchenko

PR Manager

Put this code to your website

Width: 420px-Height: 210px
comments powered by Disqus
Hot and trending ICOs
This website is using cookies. More info.